EC Microbiology

Editorial Volume 22 Issue 9 - 2026

Beyond the Culture Plate: Accelerating Genomic Revolution in Global Mycobacterial Surveillance

Rajesh Sarkar*

Department of Medical Microbiology and Immunology, Former Assistant Professor in Medical Microbiology, College of Health and Medical Sciences, Haramaya University, Ethiopia

*Corresponding Author: Rajesh Sarkar, Department of Medical Microbiology and Immunology, Former Assistant Professor in Medical Microbiology, College of Health and Medical Sciences, Haramaya University, Ethiopia.
Received: August 31, 2026; Published: September 04, 2026



To achieve global tuberculosis elimination, the international framework must prioritise proactive genomic and digital surveillance. Current traditional diagnostics facilitate underreporting of drug-resistant strains of M. tuberculosis in high-burden regions, promoting the cross-border transmission of XDR-TB. This editorial outlines an actionable, next-generation surveillance strategy to mitigate the diagnostic gaps and curtail the global spread of drug-resistant pathogens.

Keywords: Tuberculosis; Multi-Drug Resistance; Genomics; Public Health Surveillance; Disease Elimination; XDR-TB

 

  1. "Global Tuberculosis Report-2025”. Geneva (2025).
  2. Foresight Institute of Research and Translation. “FIRAT Editorial Board Institutional Research Desk”. 12 (2025).
  3. “Global Tuberculosis Report, 2026”. (2026).
  4. Zhang Mingming., et al. “Interpretation of the Global Tuberculosis Report 2025: Global Epidemic Trends and China’s Control Strategy”. Zoonoses 1 (2026).
  5. Zenner Dominik., et al. “State of the Global Tuberculosis Epidemic: Burden, Progress towards WHO End TB Strategy Targets and Systemic Challenges”. The Lancet Microbe (2026): 101433.
  6. Chen Zhi., et al. “Decoding the WHO Global Tuberculosis Report 2024: A Critical Analysis of Global and Chinese Key Data”. Zoonoses1 (2025).
  7. World Health Organization. "Global Tuberculosis Report 2023”. Geneva, (2023).
  8. Burhan Erlina., et al. “Characteristics of Drug-Sensitive and Drug-Resistant Tuberculosis Cases among Adults at Tuberculosis Referral Hospitals in Indonesia”. The American Journal of Tropical Medicine and Hygiene5 (2022): 984-991.
  9. Nimmo Camus., et al. “Evolution of Mycobacterium Tuberculosis Drug Resistance in the Genomic Era”. Frontiers in Cellular and Infection Microbiology 12 (2022): 954074.
  10. Roshdi Maleki Mehdi. “Genetic Analysis of Molecular Mechanisms of Drug Resistance in Mycobacterium Tuberculosis Against Four Major First-Line Anti-Tuberculosis Drugs (Isoniazid, Rifampin, Ethambutol, and Pyrazinamide)”. Infection and Drug Resistance 18 (2025): 4901-4915.
  11. Müller Borna., et al. “The Heterogeneous Evolution of Multidrug-Resistant Mycobacterium Tuberculosis”. Trends in Genetics: TIG3 (2013): 160-69.
  12. Figueras Albert and Joan-Ramon Laporte. “Failures of the Therapeutic Chain as a Cause of Drug Ineffectiveness”. BMJ [Clinical research ed.]7395 (2003): 895-896.
  13. "Technical Manual on Phenotypic and Genotypic DST”. WHO (2026).
  14. Naidoo Kogieleum., et al. “Rapid Diagnosis of Drug-Resistant Tuberculosis-Opportunities and Challenges”. Pathogens [Basel, Switzerland]1 (2023): 27.
  15. Haas Allison L., et al. “Limitations of the MTB/RIF Assay: An Xpert Review of 4 Clinical Cases”. Open Forum Infectious Diseases4 (2025): ofaf132.
  16. Zhang Ruiqing., et al. “Evaluation of the Xpert MTB/XDR Test for Detection of Isoniazid, Fluoroquinolones, and Second-Line Injectable Drugs Resistance to Mycobacterium Tuberculosis—Anhui Province, China”. PLOS One, edited by Sarman Singh 20.9 (2025): e0331264.
  17. Pillay Samantha., et al. “Xpert MTB/XDR for Detection of Pulmonary Tuberculosis and Resistance to Isoniazid, Fluoroquinolones, Ethionamide, and Amikacin”. Cochrane Database of Systematic Reviews, edited by Cochrane Infectious Diseases Group (2022).
  18. Penn-Nicholson Adam., et al. “Detection of Isoniazid, Fluoroquinolone, Ethionamide, Amikacin, Kanamycin, and Capreomycin Resistance by the Xpert MTB/XDR Assay: A Cross-Sectional Multicentre Diagnostic Accuracy Study”. The Lancet Infectious Diseases 22.2 (2022): 242-249.
  19. Jin Wenting., et al. “Targeted Next-Generation Sequencing: A Promising Approach for Mycobacterium Tuberculosis Detection and Drug Resistance When Applied in Paucibacillary Clinical Samples”. Microbiology Spectrum, edited by Sadjia Bekal, with Fangyou Yu and Bo Yan 13.7 (2025): e03127-24.
  20. Zhao X and K Drlica. “Restricting the Selection of Antibiotic-Resistant Mutants: A General Strategy Derived from Fluoroquinolone Studies”. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America3 (2001): S147-156.
  21. Lee Robyn S., et al. “Previously Undetected Super-Spreading of Mycobacterium Tuberculosis Revealed by Deep Sequencing”. eLife 9 (2020): e53245.
  22. Jung Sungwon. “Targeted Next-Generation Sequencing in Drug-Resistant Tuberculosis: WHO Guidance and Practical Implementation Priorities”. Biomedicines1 (2026): 93.

Rajesh Sarkar. “Beyond the Culture Plate: Accelerating Genomic Revolution in Global Mycobacterial Surveillance”. EC Microbiology 22.9 (2026): 01-04.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net